Your shopping cart is currently empty

Naptumomab (ABR-217620) is a tumor-targeted superantigen (TTS) fusion protein consisting of a Fab fragment targeting the 5T4 oncofetal antigen and a modified staphylococcal enterotoxin A (SEA/E-120). This product specifically recognizes 5T4 protein expressed on various solid tumors via the Fab fragment and potently activates T cells (primarily by binding to the TCR Vβ chain) through the superantigen component, inducing T cell-mediated cytotoxicity against tumor cells. It bypasses major histocompatibility complex (MHC) restriction to directly recruit and activate a large number of effector T cells into the tumor microenvironment.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $247 | 2-4 weeks | 2-4 weeks | |
| 5 mg | $622 | 2-4 weeks | 2-4 weeks | |
| 10 mg | $996 | 2-4 weeks | 2-4 weeks |
| Description | Naptumomab (ABR-217620) is a tumor-targeted superantigen (TTS) fusion protein consisting of a Fab fragment targeting the 5T4 oncofetal antigen and a modified staphylococcal enterotoxin A (SEA/E-120). This product specifically recognizes 5T4 protein expressed on various solid tumors via the Fab fragment and potently activates T cells (primarily by binding to the TCR Vβ chain) through the superantigen component, inducing T cell-mediated cytotoxicity against tumor cells. It bypasses major histocompatibility complex (MHC) restriction to directly recruit and activate a large number of effector T cells into the tumor microenvironment. |
| In vitro | In biochemical assays, Naptumomab binds with high affinity to 5T4-expressing tumor cells and simultaneously cross-links the T-cell receptor (TCR), leading to robust T-cell activation and proliferation; in cytotoxicity assays, the compound triggers the release of pro-inflammatory cytokines (such as IFN-γ and TNF-α) and mediates the efficient lysis of 5T4-positive renal cell carcinoma and lung cancer cell lines [1][2]. |
| In vivo | In pharmacological studies using human tumor xenograft mouse models, systemic administration of Naptumomab results in a significant infiltration of activated T cells into the tumor mass and dose-dependent inhibition of tumor growth; the treatment enhances the recruitment of effector T cells and promotes localized anti-tumor immune responses [1][2]. |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID | |
| Target | TTS |
| Cas No. | 1412892-09-1 |
| Isotype | IgG1 |
| Storage | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.